To determine the effects of IRF4 on DLBCL chemoresistance, we established OCI‐LY3 stable transfectants with lentiviral vectors encoding scrambled controls shIRF4#1 and shIRF4#2, followed by treatment with chemotherapy (DOX and R‐CHOP) or BCL2 inhibitors for 48 h. The gene discussed is IRF4; the disease is diffuse large B-cell lymphoma.